Value in HealthThis is an RSS file. You can use it to subscribe to this data in your favourite RSS reader, such as GoogleReader, or to display this data on your own website or blog. Subscribe to this data using MyMedWorm.Subscribe to this data using GoogleReader.Subscribe to this data using Bloglines.Subscribe to this data using MyYahoo.

This page shows you the latest items in this publication.

Pages: 1 2 3 4 5 6 7 8 9 10 11

525 records returned

The Cost-Effectiveness of an Extended Course (12 + 12 Weeks) of Varenicline Compared with Other Available Smoking Cessation Strategies in the United States: An Extension and Update to the BENESCO ModelEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Conclusions: A total of 12 weeks of varenicline followed by a further 12-week course for successful quitters is a highly cost-effective alternative compared with currently available smoking cessation options. (Source: Value in Health)
Source: Value in Health - November 14, 2009 Category: Global & Universal Authors: Chris Knight, Paul Howard, Christine L. Baker, Jeno P. Marton Source Type: journals

What's in a Perspective?Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
(Source: Value in Health)
Source: Value in Health - November 13, 2009 Category: Global & Universal Authors: Henry A. Glick Source Type: journals

Health State Survey-Derived Utilities in Cost-Utility Analysis—A Call to ActionEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
(Source: Value in Health)
Source: Value in Health - November 12, 2009 Category: Global & Universal Authors: Benjamin P. Geisler Source Type: journals

Labeled versus Unlabeled Discrete Choice Experiments in Health Economics: An Application to Colorectal Cancer ScreeningEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Conclusion: This study provides important insights in the feasibility and difference in results from labeled and unlabeled DCEs. The inclusion of labels appeared to play a significant role in individual choices but reduced the attention respondents give to the attributes. As a result, unlabeled DCEs may be more suitable to investigate trade-offs between attributes and for respondents who do not have familiarity with the alternative labels, whereas labeled DCEs may be more suitable to explain real-life choices such as uptake of cancer screening. (Source: Value in Health)
Source: Value in Health - November 12, 2009 Category: Global & Universal Authors: Esther W. de Bekker-Grob, Lieke Hol, Bas Donkers, Leonie van Dam, J Dik F. Habbema, Monique E. van Leerdam, Ernst J. Kuipers, Marie-Louise Essink-Bot, Ewout W. Steyerberg Source Type: journals

Use of Stabilized Inverse Propensity Scores as Weights to Directly Estimate Relative Risk and Its Confidence IntervalsEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Conclusions: Our theoretical, simulation results and real data example demonstrate that the use of the stabilized weights in the pseudo data preserves the sample size of the original data, produces appropriate estimation of the variance of main effect, and maintains an appropriate type I error rate. (Source: Value in Health)
Source: Value in Health - November 12, 2009 Category: Global & Universal Authors: Stanley Xu, Colleen Ross, Marsha A. Raebel, Susan Shetterly, Christopher Blanchette, David Smith Source Type: journals

Beyond AWP . . . Way BeyondEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
(Source: Value in Health)
Source: Value in Health - November 12, 2009 Category: Global & Universal Authors: Richard J. Willke Source Type: journals

The Impact of Differences in EQ-5D and SF-6D Utility Scores on the Acceptability of Cost–Utility Ratios: Results across Five Trial-Based Cost–Utility StudiesEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Conclusions: Much of the appeal in using QALYs as measure of effectiveness in economic evaluations is in the comparability across conditions and interventions. The incomparability of the results of cost[ndash]utility analyses using different instruments to estimate a single index value for health severely undermines this aspect and reduces the credibility of the use of incremental cost[ndash]utility ratios for decision-making. (Source: Value in Health)
Source: Value in Health - October 30, 2009 Category: Global & Universal Authors: Manuela Joore, Danielle Brunenberg, Patricia Nelemans, Emiel Wouters, Petra Kuijpers, Adriaan Honig, Danielle Willems, Peter de Leeuw, Johan Severens, Annelies Boonen Source Type: journals

A Rapid-Response Economic Evaluation of the UK NHS Cancer Reform Strategy Breast Cancer Screening Program Extension via a Plausible Bounds ApproachEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Conclusions: Because the vast majority of women aged 47 to 49 years will test negative when screened for breast cancer and most of those who test positive will actually be free of the disease, the psychological impacts of screening are likely to drive cost-effectiveness for this age group. Therefore, a research priority should be to better understand and quantify these effects. (Source: Value in Health)
Source: Value in Health - October 29, 2009 Category: Global & Universal Authors: Jason Madan, Andrew Rawdin, Matt Stevenson, Paul Tappenden Source Type: journals

Cost-Effectiveness of Screening and Optimal Management for Diabetes, Hypertension, and Chronic Kidney Disease: A Modeled AnalysisEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Conclusions: Strategies combining primary care screening of 50- to 69-year-olds for proteinuria, diabetes, and hypertension followed by the routine use of ACE inhibitors, and optimal treatment of diabetes and hypertension, respectively, have the potential to reduce death and end-stage kidney disease and are likely to represent good value for money. (Source: Value in Health)
Source: Value in Health - October 29, 2009 Category: Global & Universal Authors: Kirsten Howard, Sarah White, Glenn Salkeld, Stephen McDonald, Jonathan C. Craig, Steven Chadban, Alan Cass Source Type: journals

Good Research Practices for Measuring Drug Costs in Cost Effectiveness Analyses: Issues and Recommendations: The ISPOR Drug Cost Task Force Report—Part IEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Conclusions: Drug transaction prices not only ration current use of medication but also ration future biomedical research and development. CEA researchers should tailor the appropriate measure of drug costs to the analytic perspective, maintain clarity and transparency on drug cost measurement, and report the sensitivity of CEA results to reasonable drug cost measurement alternatives. (Source: Value in Health)
Source: Value in Health - October 29, 2009 Category: Global & Universal Authors: Joel W. Hay, Jim Smeeding, Norman V. Carroll, Michael Drummond, Louis P. Garrison, Edward C. Mansley, C. Daniel Mullins, Jack M. Mycka, Brian Seal, Lizheng Shi Source Type: journals

The Impact of Fewer Hip Fractures with Risedronate Versus Alendronate in the First Year of Treatment: Modeled German Cost-Effectiveness AnalysisEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Conclusions: Based on "real world" data the analysis supports the first line use of risedronate for the treatment of osteoporotic women in Germany. (Source: Value in Health)
Source: Value in Health - October 27, 2009 Category: Global & Universal Authors: Melissa Thompson, Margaret Pasquale, Daniel Grima, Werner Moehrke, Hans Peter Kruse Source Type: journals

Cost-Effectiveness of Scheduled Maintenance Treatment with Infliximab for Pediatric Crohn's DiseaseEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Conclusion: Scheduled maintenance treatment with infliximab (5 mg/kg) is likely to be a cost-effective treatment in children suffering from severe active CD under an 8-week maintenance program. (Source: Value in Health)
Source: Value in Health - October 26, 2009 Category: Global & Universal Authors: Yogesh Suresh Punekar, Thomas Sunderland, Neil Hawkins, James Lindsay Source Type: journals

Calibration of Disease Simulation Model Using an Engineering ApproachEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
(Source: Value in Health)
Source: Value in Health - October 26, 2009 Category: Global & Universal Source Type: journals

Good Research Practices for Measuring Drug Costs in Cost-Effectiveness Analyses: A Societal Perspective: The ISPOR Drug Cost Task Force Report—Part IIEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Conclusions: Our key recommendation is that current CEA practice acknowledge and embrace this limitation by adopting a new standard for the reference case as one of a "limited societal" or "health systems" perspective, using acquisition drug prices while including indirect costs and community preferences. The field of pharmacoeconomics also needs to acknowledge the limitations of this perspective when it comes to important questions of research and development costs, and incentives for innovation. (Source: Value in Health)
Source: Value in Health - October 26, 2009 Category: Global & Universal Authors: Louis P. Garrison Jr., Edward C. Mansley, Thomas A. Abbott III, Brian W. Bresnahan, Joel W. Hay, James Smeeding Source Type: journals

Good Research Practices for Measuring Drug Costs in Cost-Effectiveness Analyses: A Managed Care Perspective: The ISPOR Drug Cost Task Force Report—Part IIIEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Conclusion: Estimates of drug cost from the MCO perspective should include amounts paid for medication ingredients and dispensing fees, and net out copays, rebates, and other drug price reductions. Because of the evolving nature of drug pricing, ISPOR should publish a Web site where current DCTF costing recommendations are updated as new information becomes available. (Source: Value in Health)
Source: Value in Health - October 26, 2009 Category: Global & Universal Authors: Edward C. Mansley, Norman V. Carroll, Kristina S. Chen, Nilay D. Shah, Catherine Tak Piech, Joel W. Hay, James Smeeding Source Type: journals

Good Research Practices for Measuring Drug Costs in Cost-Effectiveness Analyses: An International Perspective: The ISPOR Drug Cost Task Force Report—Part VIEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Conclusion: CEA researchers conducting international pharmacoeconomic analysis should tailor the appropriate measure of drug costs to the international perspective, to maintain clarity and transparency on drug cost measurement in the context of international drug comparison and report the sensitivity of CEA results to reasonable cost conversions. (Source: Value in Health)
Source: Value in Health - October 26, 2009 Category: Global & Universal Authors: Lizheng Shi, Meredith Hodges, Michael Drummond, Jeonghoon Ahn, Shu Chuen Li, Shanlian Hu, Federico Augustovski, Joel W. Hay, Jim Smeeding Source Type: journals

Good Research Practices for Measuring Drug Costs in Cost Effectiveness Analyses: An Industry Perspective: The ISPOR Drug Cost Task Force Report—Part VEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Conclusions: Understanding and accounting for all costs and consequences of the use of a medical treatment is in the best interests of all parties involved in the prescribing, consuming, reimbursement, selling, and manufacturing of bio/pharmaceuticals. Transparency, consistency, and clear communication of costs and value are essential for appropriate decision-making and should be important goals for all parties. (Source: Value in Health)
Source: Value in Health - October 26, 2009 Category: Global & Universal Authors: Jack M. Mycka, Renato Dellamano, Eugene Mick Kolassa, Michael Wonder, Sabyasachi Ghosh, Joel W. Hay, Jim Smeeding Source Type: journals

Value of Information Analyses of Economic Randomized Controlled Trials: The Treatment of Intermittent ClaudicationEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Conclusions: 1) The optimal study for patients with intermittent claudication collects data on two key parameters for 525 patients per trial arm; and 2) we have shown that value of information analysis provides an explicit framework to determine the optimal sample size and identify key parameters for the design of future clinical trials. (Source: Value in Health)
Source: Value in Health - October 8, 2009 Category: Global & Universal Authors: Bas Groot Koerkamp, Sandra Spronk, Theo Stijnen, M. G. Myriam Hunink Source Type: journals

Impact of Body Mass Index on the Incidence of Cardiometabolic Risk Factors in Ambulatory Care Settings over 5 Years or MoreEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Conclusion: Obese patients are approximately twice as likely to develop cardiometabolic risk factors compared with those having normal weight over 5 or more years. (Source: Value in Health)
Source: Value in Health - October 7, 2009 Category: Global & Universal Authors: Qayyim Said, Carrie McAdam Marx, J. Sanford Schwartz, Rami Ben-Joseph, Diana I. Brixner Source Type: journals

Cost-Effectiveness of Using Recombinant Human Thyroid-Stimulating Hormone before Radioiodine Ablation for Thyroid Cancer: The Canadian PerspectiveEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Conclusions: The use of rhTSH before radioiodine ablation represents a reasonable allocation of costs, with the benefits to patients, hospitals, and society as a whole, obtained at modest cost. (Source: Value in Health)
Source: Value in Health - October 7, 2009 Category: Global & Universal Authors: Paul Mernagh, Arsupol Suebwongpat, Jay Silverberg, Adèle Weston Source Type: journals

Analysis of the Association between Metabolic Syndrome and Disease in a Workplace Population over TimeEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Conclusions: MetS is associated with disease and increased costs in this working population. There is an opportunity for health promotion to prevent MetS risk factors from progressing to disease status which may improve vitality for employees, as well as limit the economic impact to the corporation. (Source: Value in Health)
Source: Value in Health - October 7, 2009 Category: Global & Universal Authors: Alyssa B. Schultz, Dee W. Edington Source Type: journals

Extended-Release Trospium Chloride Improves Quality of Life in Overactive BladderEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Conclusions: Once-daily trospium 60 mg ER improved the QoL of subjects with OAB, as assessed using the KHQ and the OAB-q, in two large Phase III clinical trials. (Source: Value in Health)
Source: Value in Health - October 7, 2009 Category: Global & Universal Authors: Roger R. Dmochowski, Matt T. Rosenberg, Norm R. Zinner, David R. Staskin, Peter K. Sand Source Type: journals

ISPOR Health Policy Council Proposed Good Research Practices for Comparative Effectiveness Research: Benefit or Harm?Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
(Source: Value in Health)
Source: Value in Health - October 7, 2009 Category: Global & Universal Authors: Til Stürmer, Tim Carey, Charles Poole Source Type: journals

Establishing Optimal Requirements for Content Validity: A Work in ProgressEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
(Source: Value in Health)
Source: Value in Health - October 7, 2009 Category: Global & Universal Authors: Sheri Fehnel Source Type: journals

Budget Impact Analysis of Thrombolysis for Stroke in Spain: A Discrete Event Simulation ModelEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Conclusion: The impact of thrombolysis on society's health and social budget indicates a net benefit after 6 years, and the improvement in health grows continuously. The validation of the model demonstrates the adequacy of the discrete event simulation approach in representing the epidemiology of stroke to calculate the budget impact. (Source: Value in Health)
Source: Value in Health - October 7, 2009 Category: Global & Universal Authors: Javier Mar, Arantzazu Arrospide, Mercè Comas Source Type: journals

Good Research Practices for Measuring Drug Costs in Cost-Effectiveness Analyses: Medicare, Medicaid and Other US Government Payers Perspectives: The ISPOR Drug Cost Task Force Report—Part IVEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Conclusions: As pharmacoeconomic evaluations for coverage decisions made by US public programs grows, the need for precise and consistent estimation of drug costs is warranted. Application of the proposed recommendations will allow researchers to include accurate and unbiased cost estimates in pharmacoeconomic evaluations. (Source: Value in Health)
Source: Value in Health - October 6, 2009 Category: Global & Universal Authors: C. Daniel Mullins, Brian Seal, Enrique Seoane-Vazquez, Jayashri Sankaranarayanan, Carl V. Asche, Ravishankar Jayadevappa, Won Chan Lee, Dorothy K. Romanus, Junling Wang, Joel W. Hay, Jim Smeeding Source Type: journals

Good Research Practices for Comparative Effectiveness Research: Analytic Methods to Improve Causal Inference from Nonrandomized Studies of Treatment Effects Using Secondary Data Sources: The ISPOR Good Research Practices for Retrospective Database Analysis Task Force Report—Part IIIEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Conclusions: Valid findings of causal therapeutic benefits can be produced from nonrandomized studies using an array of state-of-the-art analytic techniques. Improving the quality and uniformity of these studies will improve the value to patients, physicians, and policymakers worldwide. (Source: Value in Health)
Source: Value in Health - September 29, 2009 Category: Global & Universal Authors: Michael L. Johnson, William Crown, Bradley C. Martin, Colin R. Dormuth, Uwe Siebert Source Type: journals

Good Research Practices for Comparative Effectiveness Research: Defining, Reporting and Interpreting Nonrandomized Studies of Treatment Effects Using Secondary Data Sources: The ISPOR Good Research Practices for Retrospective Database Analysis Task Force Report—Part IEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Conclusions: Comparative effectiveness research in the form of nonrandomized studies using secondary databases can be designed with rigorous elements and conducted with sophisticated statistical methods to improve causal inference of treatment effects. Standardized reporting and careful interpretation of results can aid policy and decision-making. (Source: Value in Health)
Source: Value in Health - September 28, 2009 Category: Global & Universal Authors: Marc L. Berger, Muhammad Mamdani, David Atkins, Michael L. Johnson Source Type: journals

Cost-Effectiveness of Temsirolimus for First Line Treatment of Advanced Renal Cell CarcinomaEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Conclusions: Temsirolimus has been shown to be clinically effective compared to interferon-[alpha] offering additional health benefits, however, with a cost per QALY in excess of £90,000, it may not be regarded as a cost-effective use of resources in some health care settings. (Source: Value in Health)
Source: Value in Health - September 25, 2009 Category: Global & Universal Authors: Martin Hoyle, Colin Green, Jo Thompson-Coon, Zulian Liu, Karen Welch, Tiffany Moxham, Ken Stein Source Type: journals

Use of Existing Patient-Reported Outcome (PRO) Instruments and Their Modification: The ISPOR Good Research Practices for Evaluating and Documenting Content Validity for the Use of Existing Instruments and Their Modification PRO Task Force ReportEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Conclusion: Published evidence of the content validity of a PRO instrument for an intended application is often limited. Such evidence is, however, important to evaluating the adequacy of a PRO instrument for the intended application. This article provides an overview of key issues involved in assessing and documenting content validity as it relates to using existing instruments in the drug approval process. (Source: Value in Health)
Source: Value in Health - September 24, 2009 Category: Global & Universal Authors: Margaret Rothman, Laurie Burke, Pennifer Erickson, Nancy Kline Leidy, Donald L. Patrick, Charles D. Petrie Source Type: journals

Cost-Effectiveness of 21 Alternative Cervical Cancer Screening StrategiesEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Conclusion: There is economic evidence to support adopting 3-year PAP + HPV + PAP-age. Budgetary resources can potentially be shifted from testing and physician services to fund the additional resource requirements for inpatient and outpatient services. (Source: Value in Health)
Source: Value in Health - September 24, 2009 Category: Global & Universal Authors: Anderson Chuck Source Type: journals

Crossing Borders: Factors Affecting Differences in Cost-Effectiveness of Smoking Cessation Interventions between European CountriesEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Conclusions: Although all INMBs were positive, there were significant differences across countries. These were primarily related to choice of discount rate and epidemiology of diseases. (Source: Value in Health)
Source: Value in Health - September 24, 2009 Category: Global & Universal Authors: Pepijn Vemer, Maureen P.M.H. Rutten-van Mölken Source Type: journals

Impact of the 1997 Canadian Guidelines on the Conduct of Canadian-Based Economic Evaluations in the Published LiteratureEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Conclusion: The current assessment has shown that the 1997 Canadian guidelines have set a minimum methodological standard within the community of "doers" conducting economic analyses from a Canadian perspective. Although there was divergence from some of the recommendations, the majority were reflected as changes in the 2006 Canadian guidelines. (Source: Value in Health)
Source: Value in Health - September 24, 2009 Category: Global & Universal Authors: Morgan E. Lim, James M. Bowen, Daria O'Reilly, C. Elizabeth McCarron, Gord Blackhouse, Robert Hopkins, Ron Goeree, Jean-Eric Tarride Source Type: journals

In or Out? Income Losses in Health State Valuations: A ReviewEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Background: In 1996 the Washington Panel controversially recommended valuing productivity costs (PC) in terms of quality-adjusted life years. The Panel's assumption that respondents in health state valuation (HSV) exercises take income losses into account could not be countered since there was no evidence regarding what people consider in HSV exercises. If they do consider income losses and if this changes HSVs, then all economic evaluations that have included PC in the numerator may have double-counted these costs. Alternatively, if respondents do not consider income losses then all past economic evaluations that have not...
Source: Value in Health - September 24, 2009 Category: Global & Universal Authors: Carl Tilling, Marieke Krol, Aki Tsuchiya, John Brazier, Werner Brouwer Source Type: journals

Reliability and Validity of a Chinese Version's Health-Related Quality of Life Questionnaire for Hepatitis B PatientsEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Conclusions: The culturally adapted questionnaire has good validity and reliability for use in Singapore. (Source: Value in Health)
Source: Value in Health - September 24, 2009 Category: Global & Universal Authors: Siew Chin Ong, Seng Gee Lim, Shu Chuen Li Source Type: journals

Cost-Effectiveness of Sorafenib for Second-Line Treatment of Advanced Renal Cell CarcinomaEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Conclusions: Sorafenib has been shown to be clinically effective compared to BSC, offering additional health benefits; however, with a cost per QALY in excess of £70,000, it may not be regarded as a cost-effective use of resources in some health-care settings. (Source: Value in Health)
Source: Value in Health - September 24, 2009 Category: Global & Universal Authors: Martin Hoyle, Colin Green, Jo Thompson-Coon, Zulian Liu, Karen Welch, Tiffany Moxham, Ken Stein Source Type: journals

Using the Incremental Net Benefit Framework for Quantitative Benefit–Risk Analysis in Regulatory Decision-Making—A Case Study of Alosetron in Irritable Bowel SyndromeEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Conclusions: This study demonstrates the potential utility of applying the INB framework to real-life decision-making, and the ability to use simulation modeling incorporating outcomes data from different sources as a benefit[ndash]risk decision aid. (Source: Value in Health)
Source: Value in Health - September 9, 2009 Category: Global & Universal Authors: Larry D. Lynd, Mehdi Najafzadeh, Lindsey Colley, Michael F. Byrne, Andrew R. Willan, Mark J. Sculpher, F. Reed Johnson, A. Brett Hauber Source Type: journals

Valuation of EQ-5D Health States in Poland: First TTO-Based Social Value Set in Central and Eastern EuropeEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Conclusions: This is the first EQ-5D value set based on TTO in Central and Eastern Europe so far. Because the values differ considerably from those elicited in Western European countries, its use should be recommended for studies in Poland. Increasing the number of health states that each respondent is asked to value using TTO seems feasible and justifiable. (Source: Value in Health)
Source: Value in Health - September 9, 2009 Category: Global & Universal Authors: Dominik Golicki, Michał Jakubczyk, Maciej Niewada, Witold Wrona, Jan J. V. Busschbach Source Type: journals

Understanding the Medical and Nonmedical Value of Diagnostic TestingEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Conclusions: The potential value created by medical diagnostics incorporates medical value as well as value associated with well-being and planning. Consideration of all three dimensions has important implications for technology assessment and value-based payment. (Source: Value in Health)
Source: Value in Health - September 9, 2009 Category: Global & Universal Authors: David W. Lee, Peter J. Neumann, John A. Rizzo Source Type: journals

The Impact of Pharmaceutical Cost Containment Policies on the Range of Medicines Available and Subsidized in Finland and New ZealandEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Conclusions: In New Zealand, medicines are heavily subsidized across therapy groups, but those uniquely subsidized were older entities. In Finland, more "newer" medicines are subsidized and available, but the level and coverage of subsidy is lower and thus, the patient cost burden is higher. The cost containment policies adopted seem to affect patients' access to medicines mainly by availability in New Zealand and by affordability in Finland. (Source: Value in Health)
Source: Value in Health - September 9, 2009 Category: Global & Universal Authors: Katri Aaltonen, Rajan Ragupathy, June Tordoff, David Reith, Pauline Norris Source Type: journals

Patient Characteristics Impacting Health State Index Scores, Measured by the EQ-5D of Females with Stress Urinary Incontinence SymptomsEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Conclusion: This article describes the characteristics of patients at the SUIT enrollment visit, and demonstrates that the number of incontinence episodes has a significant impact on the EQ-5D index score. (Source: Value in Health)
Source: Value in Health - September 9, 2009 Category: Global & Universal Authors: Douglas Tincello, Mark Sculpher, Ralf Tunn, Deborah Quail, Huub van der Vaart, Christian Falconer, Martina Manning, Louise Timlin Source Type: journals

Good Research Practices for Comparative Effectiveness Research: Approaches to Mitigate Bias and Confounding in the Design of Nonrandomized Studies of Treatment Effects Using Secondary Data Sources: The International Society for Pharmacoeconomics and Outcomes Research Good Research Practices for Retrospective Database Analysis Task Force Report—Part IIEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Conclusions: Design of nonrandomized studies of comparative effectiveness face several daunting issues, including measurement of exposure and outcome challenged by misclassification and confounding. Use of causal diagrams and restriction are two techniques that can improve the theoretical basis for analyzing treatment effects in study populations of more homogeneity, with reduced loss of generalizability. (Source: Value in Health)
Source: Value in Health - September 9, 2009 Category: Global & Universal Authors: Emily Cox, Bradley C. Martin, Tjeerd Van Staa, Edeltraut Garbe, Uwe Siebert, Michael L. Johnson Source Type: journals

The ISPOR Good Practices for Quality Improvement of Cost-Effectiveness Research Task Force ReportEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Conclusions: The QICER Task Force recommends that ISPOR implement the following: With respect to CER guidelines, that ISPOR promote harmonization of guidelines, allowing for differences in application, regional needs and politics; evaluate available instruments or promote development of a new one that will allow standardized quantification of the impact of CER guidelines on the quality of CER studies; report periodically on those countries or regions that have developed guidelines; periodically evaluate the quality of published studies (those journals with CER guidances) or those submitted to decision-making bodies (as pub...
Source: Value in Health - September 9, 2009 Category: Global & Universal Authors: William F. McGhan, Maiwenn Al, Jalpa A. Doshi, Isao Kamae, Steven E. Marx, Donna Rindress Source Type: journals

On Guidelines for Comparative Effectiveness Research Using Nonrandomized Studies in Secondary Data SourcesEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
(Source: Value in Health)
Source: Value in Health - September 9, 2009 Category: Global & Universal Authors: Sebastian Schneeweiss Source Type: journals

A Concept Taxonomy and an Instrument Hierarchy: Tools for Establishing and Evaluating the Conceptual Framework of a Patient-Reported Outcome (PRO) Instrument as Applied to Product Labeling ClaimsEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Conclusion: This analysis of PRO concepts and instruments illustrates that the taxonomy and hierarchy are applicable to PRO concepts across a wide range of therapeutic areas and provide a basis for defining the instrument conceptual framework complexity. Although the utility of these tools in the drug development, review, and approval processes has not yet been demonstrated, these tools could be useful to improve communication and enhance efficiency in the instrument development and review process. (Source: Value in Health)
Source: Value in Health - September 9, 2009 Category: Global & Universal Authors: Pennifer Erickson, Richard Willke, Laurie Burke Source Type: journals

Health State Valuations of Patients and the General Public Analytically Compared: A Meta-Analytical Comparison of Patient and Population Health State UtilitiesEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Conclusion: In contrast with Dolders et al., our results show that patients give higher valuations than members of the general public. For future cost-utility analyses, researchers should be aware of the differential effects of respondent group for the elicitation methods TTO and VAS. (Source: Value in Health)
Source: Value in Health - September 9, 2009 Category: Global & Universal Authors: Yvette Peeters, Anne M. Stiggelbout Source Type: journals

Cost-Effectiveness of Implantable Cardioverter-Defibrillators in Brazil: Primary Prevention Analysis in the Public SectorEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Conclusions: In a Brazilian scenario, where ICD cost is proportionally more elevated than in developed countries, ICD therapy was associated with a high cost-effectiveness ratio. The results were more favorable for a patient subgroup at increased risk of sudden death. (Source: Value in Health)
Source: Value in Health - September 2, 2009 Category: Global & Universal Authors: Rodrigo Antonini Ribeiro, Steffan Frosi Stella, Suzi Alves Camey, Leandro Ioschpe Zimerman, Maurício Pimentel, Luis Eduardo Rohde, Carísi Anne Polanczyk Source Type: journals

Prevalence of Respiratory Syncytial Virus (RSV) Risk Factors and Cost Implications of Immunoprophylaxis to Infants 32 to 35 Weeks Gestation for Health Plans in the United StatesEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Conclusion: Expanding the AAP RF criteria to include PSE, CLC, and YCA would identify more 32 to 35 wGA infants at high risk for severe RSV disease at an acceptable budget impact. (Source: Value in Health)
Source: Value in Health - August 24, 2009 Category: Global & Universal Authors: Leonard R. Krilov, Debra L. Palazzi, Ancilla W. Fernandes, Robert W. Klein, Parthiv J. Mahadevia Source Type: journals

Probabilistic Sensitivity Analysis: Be a BayesianEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Conclusions: Input probability distributions should not be based on the likelihood of the data, but on the Bayesian posterior distribution calculated from this likelihood and an explicitly stated prior distribution. (Source: Value in Health)
Source: Value in Health - August 20, 2009 Category: Global & Universal Authors: Hendriek C. Boshuizen, Pieter H. M. van Baal Source Type: journals

Comparative Analysis of Length of Stay, Total Costs, and Treatment Success between Intravenous Moxifloxacin 400 mg and Levofloxacin 750 mg among Hospitalized Patients with Community-Acquired PneumoniaEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Conclusions: In-hospital treatment of CAP with IV moxifloxacin 400 mg or IV levofloxacin 750 mg was associated with similar hospital LOS and costs in propensity-matched cohorts. (Source: Value in Health)
Source: Value in Health - August 19, 2009 Category: Global & Universal Authors: Howard Friedman, Xue Song, Simone Crespi, Prakash Navaratnam Source Type: journals